Thank you for submitting your manuscript to the EMBO journal. Your study has now been seen by three referees and their comments are provided below. As you can see the referees appreciate that we gain insight into the role of the Hippo pathway in microglia function and find the analysis interesting. They raise a number of important points that would have to be addressed for further consideration here. In particular, some further molecular insight into how Daxx/MST1 regulates cell death in microglia would be needed for publication here. Should you be able to address these criticisms in full, we could consider a revised manuscript. I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
The paper by Yun et al focuses on the role of MST1 in microglia, in particular upon treatment with IFN-gamma. They show that MST1 interacts with Daxx, a nuclear protein involved in chromatin regulation and cell death. Both proteins are regulated by IFN-gamma. Daxx is required for activation of MST1 by IFN. This may occur through Daxx-mediated induction of MST1 homodimerization and nuclear translocation. Both MST1 and Daxx are required for IFN-gamma induced cell death of microglial cells. This is a report with potential implications for the understanding of microglia function/regulation and of regulation of the Hippo pathway. However, it is rather preliminary and a number of experiments are required to strengthen it and increase its impact. One main point is that the authors failed to explain mechanisms underlying cell death regulation by MST1/Daxx. This is a key point that needs to be addressed. I have raised a number of other points, which are listed below.
-It is very surprising that the authors did not include very relevant information about the Hippo pathway in the introduction and failed to discuss this properly in the discussion section. This is definitely a shortcoming that needs to be corrected.
-Daxx is a PML-interacting protein, so it is a bit surprising that the authors have not checked whether PML is expressed in microglia and if MST1 and Daxx associate/colocalise with PML. This could provide insights into the mechanisms underlying Daxx/MST21 function in microglia.
- Fig. 2A does not show Daxx in IP samples. This is rather surprising, as it is an essential experiment. The IP has to be repeated, otherwise it is difficult to conclude that the two proteins definitely interact at the endogenous level.
-The authors never considered that Daxx itself could be a target of MST1. This should be determined.
-The effect of Daxx siRNA on MST1 activation needs to be quantified. At present, it is difficult to appreciate differences in activation.
- Fig 6B: Quantification of the effect of Daxx siRNA on MST1 localisation is missing. Showing just one or two cells is not acceptable. A careful quantification of number of cells with different localization patterns needs to be included. In the same figure, it is unclear why levels of cytoplamic MST1 upon IFN-gamma are reduced in IF experiments, while in the WB there are equal levels in untreated and treated cells. This is quite worrying and authors need to confirm that the antibody is really specific for MST1.
- Fig. 6D also needs quantification of different localization patterns. - Fig. 7 : the authors need to determine whether overexpression of MST1 or DAxx induces cell death even in the absence of IFN-gamma. If this is case, authors will be then able to test whether MST1-induced cell death requires Daxx. Otherwise, it is difficult to conclude that the two proteins act together in inducing cell death. As mentioned above, insights into how the two proteins regulate cell death would increase the impact of the paper and potentially strengthen the idea of a Daxx/MST1 pathway. -Finally, the authors need to show that Daxx is induced by IFN-gamma in microglia in vivo. Antibodies for IHC/IF for tissue staining are available. This is another key point.
Referee #2 (Remarks to the Author):
The manuscript by Yun et al. reports the the specifc apoptosis of microgial brain macrophages in response to interferon-g stimulation. In particular they delinate a pathway which requires the proapoptotic protein DAXX and the tumour suppressor kinase MST1 leading the the phosphorylation of H2B.
The manuscript was well written with both the experimental design and execution being of a very high standard and succinctly indicating the importance of their findings. There are a few conceptual comments I would like to point out they would strengthen their conclusions or should be discussed. 1) Does caspase inhibition affect the H2B phosphorylation due to MST1 full length. If the DAXX mediated H2B phosphorylation is due to full length MST1, as it does appear to be, then either caspase inhibition or caspase site mutated MST1 would not affect the p-H2B levels.
2) The relevance of Jak involvement is not clear and is mentioned by way of the inhibitor. It is not clear how relevant this is (ie no discussion) or how specific the inhibitor is?
3)MST kinases have been recently indicated to regulate RCC1 and nuclear import/export (Dallol et al Curr Biol 2009 )which may complicate the localisation of daxx and Mst when over expressed. Indicating no effect of expression on shuttling of Stat or Erk for example may help.
4)The authors tested Mww45 and Rassf1 -/-cells, however Rassf5/Nore1B/Rapl has been described to regulate MST kinase in immune cells and therefore would be a more appropriate control for daxx mediated activation. 5) Can this pathway be seen in other macrophage populations and/or in humans and therefore increase the relevance to human disease?
Referee #3 (Remarks to the Author):
In this very nice study, Yun et al. provide new mechanistic information about a biological phenomenon that remains largely unexplored despite its high relevance for brain homeostasis, that is activation-induced cell death (AICD) of microglia. In a set of very well performed and controlled experiments that range from in vitro/test tube assays to in vivo/animal experiments and take advantage of "classical" as well as "modern" technologies, they unravel the key roles played by Daxx and MST1 in the cell death induced by IFN-gamma. They convincingly demonstrate that IFNgamma stimulation leads to upregulation of Daxx expression that mediates activation of MST1 leading to microglia death. These are novel pieces of information that also further our understanding of the interactions between Daxx and MST1, namely in terms of the regulation of MST1 activity. I however am missing a certain level of discussion of the data with regards to what has been published, as mentioned under the points 2 and 6 below. The authors would improve the quality of their manuscript by taking care of this issue.
Specific comments 1-the structure of the Introduction is not in line with that of the Abstract. It would make more sense to start with the issue of AICD in microglia, continue with what we know about it or what we do not know and then why it is important-interesting to study MST1 in that context. In the present structure, the link made between MST1 and IFN-gamma induced apoptosis in microglia is very weak.
2-most of the work addressing microglia AICD has involved stimulation by a combination of LPS and IFN-gamma. What triggered the authors to use only IFN-gamma ? They may wish to comment on this point in the Introduction and to introduce to a larger extent what is already know about the mechanisms or effectors of AICD in microglia.
3-the authors cite a paper from Roy et al. in the Introduction as if it would be a reference for AICD in microglia. To my knowledge, there is no investigation of AICD in this paper.
4-page 8, 2nd paragraph, 6th line: typographic mistake: homodimer(i)zation 5-page 10, 15th line: I would rephrase the sentence as follows: "As shown in Figures 1C and 2E , IFN-gamma also induced the phosphorylation of....". The reader otherwise expects new results, which is not the case.
6-given the known links between IFN-gamma and nitric oxide (NO) production, I am missing a discussion of the current results with regards to work that has been reported, namely on the role of nitric oxide in AICD. The authors speak of "cell lysates" = they most likely mean "cell homogenates". There is no description or reference in Materials and Methods about the method used to prepare homogenate and to separate nuclear from cytosolic fractions. Figure 7A : "Apoptosis" was measured according to a morphological criterium. Why not with the Tunel assay (as in 1B) or with labelling with Annexin V/PI as in 7B ? It is not clear for the reader why this or that different method is used to measure cell death at different steps of the work.
10-
11-Materials and Methods: -in section "Cell culture and DNA transfection", the "and DNA transfection" should be removed since there is no mention of transfection method in this section. -primary microglia: primary cultures can be easily "contaminated" by other cell types. What evidence do we have about the quality of the cultures used ? The authors should clarify this point (by referring to their previous published work or showing relevant data).
-the source (provider) of IFN-gamma should be mentioned in Materials and Methods or in the text. Please consider our revised manuscript entitled "Daxx mediates activation-induced cell death in microglia by triggering MST1 signaling" (MS# EMBOJ-2010-75914) for publication in the EMBO Journal. We include additional data in our revised manuscript according to the helpful comments by the reviewers. The additional data and the changes that we made in the revised manuscript are following:
[Referee #1] (1) "One main point is that the authors failed to explain mechanisms underlying cell death regulation by MST1/Daxx. This is a key point that needs to be addressed. "
We have now included additional data and discussion related to the mechanism of MST1-mediated cell death in the revised manuscript, according to the insightful point of this Referee. Our explanation of the new data and the related discussion added in the manuscript are as follows:
We have shown in this manuscript that both Daxx and MST1 play the key role in microglial cell death induced by the proinflammatory cytokine IFN-. Additionally, the MST1-mediated phosphorylation of histone H2B observed in IFN--treated microglia implicates that this phosphorylation be one of the downstream events of the MST1-mediated cell death of microglia, given that MST1 promotes chromatin condensation associated with apoptosis by means of the Ser14 phosphorylation of histone H2B (Cheung et al, Cell 113:507, 2003) . Since NO has been shown to be one of the cytotoxic mediators for AICD in microglia, one interesting question would be what is the mechanistic relationship between MST1 and NO in IFN--induced microglial cell death. Related to this issue, we observed that siRNA-mediated depletion of MST1 did not affect the IFN--induced NO production (Supplementary Figure S12) , suggesting that MST1 signaling is not involved in IFN--induced NO production in microglia. These data also implicate that NO may not be involved in the signaling events downstream of MST1 in IFN--induced cell death in microglia. With these findings, one may propose that MST1 and NO mediate IFN--induced microglial cell death through independent mechanisms. We do not rule out, however, another possibility that NO may act upstream of MST1 in the processes of IFN--induced microglial cell death. The stress-activated mitogen-activated protein kinases (MAPKs) such as JNK and p38 MAPK might be another potential targets acting downstream of MST1 in IFN--induced microglial cell death. In this regard, previous studies showed that MST1 appears to promote apoptotic events through the up-regulation of the stress-induced protein kinases including JNK and p38 MAPK under certain conditions (Graves et al, EMBO J 17:2224 EMBO J 17: , 1998 Ura et al, Genes Cells 6:519, 2001 ). However, our data indicate that either SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor) did not inhibit IFN--induced apoptosis in BV-2 cells (Supplementary Figure S13) , implicating that JNK or p38 kinase may not be associated with the MST1-mediated signaling processes in IFN--induced microglial cell death. Regardless of the target factors of MST1 responsible for MST1-mediated cell death, our results in this manuscript suggest that Daxx and MST1 may be the key players of IFN--induced cell death of activated microglia.
(
2) "It is very surprising that the authors did not include very relevant information about the Hippo pathway in the introduction and failed to discuss this properly in the discussion section. This is definitely a shortcoming that needs to be corrected"
We have now included the information of the Hippo pathway in the introduction and discussion sections in the revised manuscript.
(3) "Daxx is a PML-interacting protein, so it is a bit surprising that the authors have not checked whether PML is expressed in microglia and if MST1 and Daxx associate/colocalise with PML.
We observed that PML is expressed in microglia and that IFN-treatment increases the abundance of PML in microglial BV-2 cells. Then, we examined whether PML physically associates with MST1 and Daxx in BV-2 cells. Co-immunoprecipitation data indicate that PML associated with Daxx in the cells and this association was increased in the cells after IFN-treatment. However, PML did not associate with MST1 in the same cells regardless of IFN-treatment. These data are now shown in Supplementary Figure S8A in the revised manuscript. We also examined the IFN--induced activation of MST1 activity in BV-2 cells transfected with either control or PML siRNA. Immunoblot analysis with antibodies specific for MST1 phosphorylated on Thr183 (the active form of MST1) showed that RNAi-mediated knockdown of PML did not affect the IFN--induced activation of MST1 in BV-2 cells. These data are now shown in Supplementary Figure S8B in the revised manuscript.
(4) " Fig. 2A We repeated this experiment and now add new data including Daxx immunoblot of the IP samples in Figure 2A in the revised manuscript. Figure S3 in the revised manuscript. In these experiments, we prepared MST1 immunoprecipitates from BV-2 cells that had been untreated or treated with interferon-. Then, we examined whether the MST1 immunoprecipitates could phosphorylate Daxx in vitro. The in vitro kinase assay data indicated that MST1 phosphorylates histone H2B but not Daxx.
(6) "The effect of Daxx siRNA on MST1 activation needs to be quantified. At present, it is difficult to appreciate differences in activation."
We quantified the intensity of the bands corresponding to histone H2B phosphorylation in two independent experiments ( Figure 2D ) or in three independent experiments ( Figure S4 ) by densitometry. We now show these results in the additional graphs in Figure 2D and Figure S4 of the revised manuscript. -We quantified the effect of Daxx siRNA on MST1 localisation and have now included the data in Figure 6C of the revised manuscript. The numbers of cells having nuclear MST1 were counted in eight randomly chosen fields in a confocal microscope (Carl Zeiss, LSM 510 META), and expressed as the percentages relative to total numbers of cells. At least 200 cells were scored for each treatment.
-Anti-MST1 antibody used for immunostaining in Figure 6C was purchased from Cell Signaling Technology, Inc. (Catalog #3682). This antibody is sold by the company after being purified by protein A and peptide affinity chromatography. In order to examine the specificity of this antibody, we performed immunostaining of BV-2 cells with the antibody after pre-incubating it in the absence or presence of purified His6-tagged MST1 protein. The results, as shown below, show that preincubation of the antibody with His6-MST1 effectively blocks immunostaining of endogenous MST1 in BV-2 cells with this antibody. With these data, we conclude that this antibody is specific for MST1.
(Experimental procedure) BV-2 cells were fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100 solution, and then immunostained with anti-MST1 antibody in the absence (left) or presence of His-tagged MST1 (right). Before being used for immunostaining, anti-MST1 antibody (1 g) was pre-incubated with purified His-MST1 protein (30 g) in PBS(100 l) for overnight. Images were acquired by confocal microscopy (Carl Zeiss, LSM 510 META). Scale bar, 20 m (8) " Fig. 6D 
also needs quantification of different localization patterns."
We quantified the effect of Daxx siRNA on the presence of the phosphorylated histone H2B in the nucleus and have now included the data in Figure 6D of the revised manuscript. The numbers of nuclei with the phosphorylated form of histone H2B were counted in randomly chosen fields in a confocal microscope (Carl Zeiss, LSM 510 META), and expressed as the percentages relative to total numbers of nuclei. At least 300 cells were scored for each treatment.
(9) " Fig. 
7: the authors need to determine whether overexpression of MST1 or Daxx induces cell death even in the absence of IFN-gamma. If this is case, authors will be then able to test whether MST1-induced cell death requires Daxx..."
We have tried to transiently transfect BV-2 cells with plasmid vectors encoding either MST1 or Daxx in order to perform apoptosis experiments as suggested by Referee #1. However, transfection efficiency was too poor to perform the experiments in these cells. We tried the similar transfection experiments in primary rat microglia, but observed the same problem. Three different transfection methods were used in these experiments: (1) liposome (Lipofectamine 2000, Invitroten); (2) electroporation; (3) nanoparticle (Xfect, Clontech). We did not try stable transfection because cells stably overexpressing apoptosis-inducing proteins would die away during antibiotic selection of stable transfectants.
(10) "the authors need to show that Daxx is induced by IFN-gamma in microglia in vivo. Antibodies for IHC/IF for tissue staining are available. This is another key point."
We performed immunohistochemical staining with antibodies to Daxx and Iba-1 (a microglial marker) and have now included the data in Supplementary Figure S11 in the revised manuscript.
Our data indicate that induction of Daxx expression in microglia was observed in the cerebral cortex in mouse after one day of IFN-gamma injection.
[ We observed that a pan-caspase inhibitor z-VAD did not affect the H2B phosphorylation induced by IFN-gamma, as shown below in panel A. It is also noteworthy that IFN-gamma did not induce the cleavage (activation) of caspase-3 while it induced the H2B phosphorylation in BV-2 cells, as shown below in panel B.
(experimental procedure) A, BV-2 cells were left untreated or treated with IFN-(100 U/ml) for 16 h. Where indicated, cells were pretreated with 50 M z-VAD-fmk for 2 h prior to the IFN-treatment. Cell lysates were immunoblotted with antibodies to Ser14-phosphorylated histone H2B (p-H2B) or to histone H2B. B, BV-2 cells were left untreated or treated with IFN-(100 U/ml) for 16 h. Cell lysates were immunoblotted with antibodies to phospho-H2B, to H2B, or to caspase-3.
2) "The relevance of Jak involvement is not clear and is mentioned by way of the inhibitor. It is not clear how relevant this is (ie no discussion) or how specific the inhibitor is?"
We used AG490 in Supplementary Figure S2 in order to examine whether IFN-induces Daxx expression in microglial cells through the Jak signaling pathway. AG490 was previously shown to inhibit a tyrosine kinase Jak-2 while it does not affect other non-receptor tyrosine kinases including Lck, Lyn, Btk, Syk, and Src (Meydan et al., Nature 379:645, 1996) . AG490 has been used to block the IFN-ñinduced Jak/STAT signaling events (Woszczek et al., J. Immunol. 178:5262, 2007; Gallmeier et al., J. Cell. Physiol. 203:209, 2005; Gorina et al., J. Neurochem. 92:505, 2005) .
(3) "MST kinases have been recently indicated to regulate RCC1 and nuclear import/export (Dallol et al Curr Biol 2009) which may complicate the localisation of daxx and Mst when overexpressed. Indicating no effect of expression on shuttling of Stat or Erk for example may help."
As suggested by this Referee, we examined the effect of We have now included new data in Supplementary Figure S7 of the revised manuscript. In this experiment, we examined MST1 activity in BV-2 cells transfected with GFP control or Rassf5 siRNA and observed that siRNA-mediated depletion of Rassf5 did not affect MST1 activation induced by IFN--Daxx signaling in the cells (Supplementary Figure S7) .
(5) "Can this pathway be seen in other macrophage populations and/or in humans …?" We examined the effect of IFN-on Daxx expression and MST1 activity in rat alveolar macrophages, and observed that IFN-increases Daxx abundance as well as MST1 activity in primary rat alveolar macrophages. We have now included these data in Supplementary Figure S13 in the revised manuscript.
[Reviewer #3] In our initial experiments, we observed that IFN-gamma alone induced the activation (the expression of proinflammatory cytokines such as TNF-alpha and interleukin 6 and the generation of nitric oxide) and subsequent death of microglia cells. Thus, IFN-gamma was able to induce AICD in microglia even in the absence of other inflammatory stimuli such as LPS. With these initial findings, we decided to use only IFN-gamma in our study investigating AICD in microglia.
As suggested by this Referee, we have now added the known apoptotic mediators of microglial AICD in the Introduction section in the revised manuscript. We have now included new data (Supplementary Figure S12) and the information regarding a role of nitric oxide in IFN-gamma-induced microglial cell death in the discussion section of the revised manuscript. As this Referee mentioned, nitric oxide (NO) is one of the players mediating AICD in microglia. Noticeably, siRNA-mediated depletion of MST1 did not affect the IFN--induced NO production (Supplementary Figure S12) , suggesting that MST1 signaling is not involved in IFN--induced NO production in microglia. These data also implicate that NO may not be involved in the signaling events downstream of MST1 in IFN--induced cell death in microglia. With these findings, one may propose that MST1 and NO may mediate IFN--induced microglial cell death through independent mechanisms. We do not rule out, however, another possibility that NO may act upstream of MST1 in the mechanism of IFN--induced AICD. In Figure 1B , the percentage of TUNEL-positive cells was quantitated by counting nuclei. That is, data were expressed as the percentages of TUNEL-positive nuclei [(the number of TUNEL9 positive nuclei/the number of DAPI-stained total nuclei) x 100]. About 1,000 cells were examined per a group. It was previously reported that BV-2 cells have many of the morphological, phenotypical, and functional properties of primary microglial cells (Blasi et al., J. Neuroimmunol. 27, 229-237, 1990 ). BV2 cells are positive for MAC1 and MAC2 antigens (microglia markers), and are negative for glial fibrillary acidic protein (a marker for astrocytes) and galactocerebroside (a marker for oligodendrocytes) antigens. The efficiency of transfection of primary cells with siRNA oligonucleotides was more than 80 % when we examined it with fluorescein attached oligonucleotides. We did not measure the efficiency of transfection of BV-2 and 293T cells because we did not perform the RNAi experiement using siRNA oligonucleotides in those cells in this manuscript.
(9) " Figure 6B : The authors speak of "cell lysates" = they most likely mean "cell homogenates". There is no description or reference in Materials and Methods about the method used to prepare homogenate and to separate nuclear from cytosolic fractions."
We have now added the procedure of the preparation of the nuclear and cytosolic fractions in the Materials and Methods section of the revised manuscript.
(10) Figure 7A :
"Apoptosis was measured according to a morphological criterium. Why not with the Tunel assay (as in 1B) or with labelling with Annexin V/PI as in 7B ? It is not clear for the reader why this or that different method is used to measure cell death at different steps of the work."
As suggested by this Referee, we performed the TUNEL assay and have now included the TUNEL assay data in Figure 7A of the revised manuscript. -We have now described DNA transfection in section "Cell culture and DNA transfection" of the Materials and Methods in the revised manuscript.
-We examined the quality of primary microglia by immunostaining with antibody to the microglial marker Iba-1. More than 95 % of the cells in primary cultures were Iba-1-positive cells, as shown below. We described it in section "Cell culture and DNA transfection" of the Materials and Methods in the revised manuscript.
(experimental procedure) Primary rat microglia cells were fixed, permeabilized, stained with DAPI, and then immunostained with primary antibody to microglia specific marker IBA-1, then incubated with Alexa 488-conjugated anti-rabbit secondary antibody(Invitrogen). The fluorescent image was visualized with a fluorescence microscope (Carl Zeiss axiovert 200). Scale bar, 100 m.
-The name of the vender of IFN-gamma has been now included in the Materials and Methods, as suggested by this Referee. Thank you for considering our revised manuscript for publication. Thank you for submitting your revised manuscript to the EMBO journal. Your study has now been seen by the original referee #1 and 3. Both referees appreciate that the revised version has improved. However referee #1 still has a few outstanding concerns that should be addressed in a final round of revision. Regarding point #1 -further mechanistic insights -don't worry about this point. However the two other points should be addressed. When you upload the revised version, please also upload a detailed point-by-point response.
Yours sincerely, Editor The EMBO Journal _____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
The manuscript is improved. Nonetheless, some of my previous points have not been fully addressed. In particular, data on localisation of DAXX in vivo is not convincing.
-The paper still lacks mechanistic details to explain how DAXX and MST1 regulate cell death in this system. I appreciate that the authors have attempted to address this point. Overall, I think this should not preclude publication.
-I am still not convinced about the IF experiments included in figure 6 . While images show a clear decrease in cytoplasmic MST1 upon IFN, the subcellular fractionation does not show any change of MST1 in the cytoplasmic fraction. In my view, these IF experiments (6C) are unconvincing and should be removed. The subcellular fractionation is instead quite convincing.
- Figure S11 : it is not clear whether DAXX is nuclear or cytoplasmic in the tissue sections shown. The authors should include a higher magnification image and determine whether DAXX is nuclear or cytoplasmic. This is a key point. If convincing, this figure should be part of the main figures.
I am satisfied with the answers the authors made to the questions I raised and I thank them for their work. I recommend the publication in The EMBO Journal of this revised version, which quality has been improved through addition of new sets of data, reference to current literature and critical discussion of the data. Please consider our revised manuscript entitled "Daxx mediates activation-induced cell death in microglia by triggering MST1 signaling" (MS# EMBOJ-2010-75914R) for publication in the EMBO Journal. We include additional data in our revised manuscript according to the helpful comments by the referee #1 and Editor. The additional data and the changes that we made in the revised manuscript are following: 
